Clinical Trials Browser

Hypoxia, Carcinoma, Renal Cell, Kidney Neoplasms

NCT06787053 2025-05-29

SELECT

Recruiting

30 enrolled

Genitourinary

Hypoxia, Neoplasms, Prostatic Neoplasms

NCT06475261 2025-03-07

Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

Recruiting

50 enrolled

GenitourinaryGynecologic

Hypoxia, Ovarian Neoplasms, Acute Kidney Injury

NCT05702619 2023-01-27

HYPROGEN

Unknown

60 enrolled

Genitourinary

Hypoxia, Prostatic Neoplasms

NCT03365076 2023-01-09

EXIPOX

Phase NA Terminated

1 enrolled

Genitourinary

Hypoxia, Motor Activity, Prostatic Neoplasms

NCT02584400 2019-03-08

HX4 SD

Phase 2 Terminated

1 enrolled

CNSGastrointestinalGenitourinary

Hypoxia, Brain Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Rectal Neoplasms

NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Phase 1 Unknown

69 enrolled

DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Phase 1/2 Completed

71 enrolled

GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00884520 2010-03-16

VM4-037

Phase EARLY_PHASE1 Completed

16 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Hypoxia, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms

Clinical Trials

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

SELECT

Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

HYPROGEN

EXIPOX

HX4 SD

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

VM4-037